Albuvirtide

Drug Profile

Albuvirtide

Latest Information Update: 27 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Frontier Biotechnologies
  • Class Antivirals; Maleimides; Peptides
  • Mechanism of Action HIV envelope protein gp41 inhibitors; HIV fusion inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration HIV infections

Most Recent Events

  • 25 Jul 2017 3BNC 117 antibody licensed to Frontier Biotechnologies for combination studies with albuvirtide worldwide for the prevention and treatment of HIV infections
  • 25 Jul 2017 Frontier Biotechnologies plans a clinical trial for HIV infections (Combination therapy) in 2018
  • 06 Jun 2016 Frontier Biotechnologies announces intention to submit NDA to China Food and Drug Administration in 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top